Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Adaptimmune Therapeutics

06/05/2021 19:11

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended
in March. The mean expectation of six analysts for the quarter
was for a loss of 25 cents per share.
* Revenue fell 43% to $434.00 thousand from a year ago​; 
analysts expected $1.83 million.
* Adaptimmune Therapeutics PLC's reported EPS for the quarter
was a loss of 24 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Adaptimmune Therapeutics PLC shares had fallen by 3.6% this
quarter and lost 5.0% so far this year.
* The company reported a quarterly loss of $37.76 million.
* Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $12.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 06:11 p.m. GMT. ​All
figures in US Dollars.​